SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

Group 1 - Halper Sadeh LLC is investigating Pulmatrix, Inc. and Entero Therapeutics, Inc. for potential violations of federal securities laws and breaches of fiduciary duties to shareholders related to their respective mergers [1][2] - In the proposed merger between Pulmatrix, Inc. and Cullgen Inc., Pulmatrix stockholders are expected to own approximately 3.6% of the combined company upon closing [1] - In the merger between Entero Therapeutics, Inc. and Journey Therapeutics, Inc., Journey shareholders will acquire 99% of the equity of Entero upon closing [2] Group 2 - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief and benefits on behalf of shareholders [3] - Shareholders are encouraged to contact Halper Sadeh LLC free of charge to discuss their legal rights and options [4] - Halper Sadeh LLC represents investors globally who have been victims of securities fraud and corporate misconduct, recovering millions on behalf of defrauded investors [4]